CO2021008988A2 - Combinación de dextrometorfano y bupropión para el tratamiento de depresión - Google Patents

Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Info

Publication number
CO2021008988A2
CO2021008988A2 CONC2021/0008988A CO2021008988A CO2021008988A2 CO 2021008988 A2 CO2021008988 A2 CO 2021008988A2 CO 2021008988 A CO2021008988 A CO 2021008988A CO 2021008988 A2 CO2021008988 A2 CO 2021008988A2
Authority
CO
Colombia
Prior art keywords
dextromethorphan
bupropion
depression
treatment
combination
Prior art date
Application number
CONC2021/0008988A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of CO2021008988A2 publication Critical patent/CO2021008988A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN Se divulgan las formas de dosificación, sistemas de suministro de fármacos y métodos relacionados con la liberación sostenida de dextrometorfano o efectos terapéuticos mejorados. Típicamente, bupropión o un compuesto relacionado se administra por vía oral a un ser humano a ser tratado con o que es tratado con dextrometorfano.
CONC2021/0008988A 2019-01-07 2021-07-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión CO2021008988A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789431P 2019-01-07 2019-01-07
US201962789451P 2019-01-07 2019-01-07
US201962789488P 2019-01-07 2019-01-07
US201962789446P 2019-01-07 2019-01-07
PCT/US2020/012612 WO2020146412A1 (en) 2019-01-07 2020-01-07 Combination of dextromethorphan and bupropion for treating depression

Publications (1)

Publication Number Publication Date
CO2021008988A2 true CO2021008988A2 (es) 2021-09-09

Family

ID=71521902

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008988A CO2021008988A2 (es) 2019-01-07 2021-07-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Country Status (16)

Country Link
EP (1) EP3908270A4 (es)
JP (1) JP2022516361A (es)
KR (1) KR20210110654A (es)
CN (4) CN114712356A (es)
AU (2) AU2020207261B2 (es)
BR (1) BR112020025902A2 (es)
CA (2) CA3223187A1 (es)
CL (1) CL2021001810A1 (es)
CO (1) CO2021008988A2 (es)
CR (1) CR20210368A (es)
EC (1) ECSP21051833A (es)
IL (1) IL284663A (es)
MX (1) MX2021008247A (es)
PE (1) PE20212249A1 (es)
SG (1) SG11202106392RA (es)
WO (1) WO2020146412A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
AU2021390502A1 (en) * 2020-12-01 2023-06-22 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for reduction of suicide risk in depression patients
CN117693336A (zh) * 2021-07-21 2024-03-12 安泰赛普生物风投二代有限责任公司 抑郁症的治疗
WO2023225511A1 (en) * 2022-05-17 2023-11-23 Antecip Bioventures Ii Llc Treatment of depression
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
SG11201502425WA (en) * 2012-10-11 2015-05-28 Ix Biopharma Ltd Solid dosage form
US20150342946A1 (en) * 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
US10512643B2 (en) * 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015069809A1 (en) * 2013-11-05 2015-05-14 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US20190111047A1 (en) * 2014-09-14 2019-04-18 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
KR20240027872A (ko) * 2014-11-21 2024-03-04 안테씨프 바이오벤쳐스 투 엘엘씨 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법

Also Published As

Publication number Publication date
CA3126062C (en) 2024-02-06
SG11202106392RA (en) 2021-07-29
MX2021008247A (es) 2021-08-16
CR20210368A (es) 2021-12-10
BR112020025902A2 (pt) 2021-07-13
CN112437659B (zh) 2022-04-12
AU2020207261B2 (en) 2023-04-13
ECSP21051833A (es) 2021-11-18
CN114712357A (zh) 2022-07-08
CL2021001810A1 (es) 2022-03-04
CA3126062A1 (en) 2020-07-16
WO2020146412A1 (en) 2020-07-16
PE20212249A1 (es) 2021-11-24
EP3908270A4 (en) 2022-02-16
CA3223187A1 (en) 2020-07-16
JP2022516361A (ja) 2022-02-25
IL284663A (en) 2021-08-31
AU2023204348A1 (en) 2023-07-27
CN114712358A (zh) 2022-07-08
EP3908270A1 (en) 2021-11-17
AU2020207261A1 (en) 2021-07-08
CN114712356A (zh) 2022-07-08
CN112437659A (zh) 2021-03-02
KR20210110654A (ko) 2021-09-08

Similar Documents

Publication Publication Date Title
CO2021008988A2 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
AR065917A1 (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor
PA8517701A1 (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
UY37413A (es) Formulaciones de liberación inmediata de oprozomib